Biotech stocks have been experiencing a healthy bounce, with the largest ETF that tracks the group recently hitting an all-time high following the announcement from Moderna that it was seeing early positive results with its coronavirus vaccine candidate. Some traders are cautioning investors to “tread carefully” when it comes to buying in to biotech stocks at their current levels, however,…
It’s the most popular investing theme this year: COVID-19 vaccine producers. However, the recent reversal of fortunes for the stock of one biotech firm – whose stock had nearly tripled since the beginning of March when the firm announced it was working on a vaccine for the novel coronavirus – illustrates the risk involved with “chasing vaccine hype”. For more,…
Anticipating that the market will continue to stage a recovery, and possibly even return to all-time highs next year, the author of today’s article notes that “investors are scanning the Street for compelling plays, hoping to snap up stocks before share prices set off on an upward trajectory. For more risk-tolerant investors, penny stocks, or names trading for less than…
When it comes to the nascent – but rapidly growing – gene editing space, the author of today’s article notes that “sector players are rapidly making progress in combating rare or difficult to treat diseases that traditional chemical based drugs simply cannot accomplish.” With the market for gene editing therapies expected to grow by over 18% annually, he highlights two…
Cannabis investors who bet that marijuana stocks would benefit from an increase in demand for cannabis products during the coronavirus lockdowns have largely been disappointed. As today’s article notes, even if demand for marijuana did rise with people stuck at home, “it hasn’t translated to gains for major cannabis producers.” Is more disappointment ahead from marijuana stocks? For more, CLICK…
Each of these three small-cap biotech stocks surged more than 100% last week. The author of today’s article notes that “It isn’t unusual to see small-cap biotechs with nine-figure market caps continue to make further gains, but they don’t always continue rising.” So which of these three small-cap biotechs might be at the beginning of a much larger move higher?…
Morgan Stanley’s chief US equity strategist believes that stocks hit their true bottom on March 23rd – and that the current rally could well lead to a true recovery. To prepare for the next bull run, he’s advising clients to buy into small-cap stocks, so today’s article highlights “three micro-cap penny stock companies with super-low entry costs (a dollar per…
“Veteran players of the stock picking game know that biotechs are capable of delivering a win at what feels like the drop of a hat,” notes the author of today’s article, who proceeds to highlight three biotech stocks, identified by investment firm Wedbush, with the potential to be game-changers. For these three Buy-rated biotech stocks with triple-digit upside potential, CLICK…
Today’s article examines a particular, well-established anomaly of the stock market – the short-term reversal effect – and how active traders can use a simple rotational strategy to take advantage of this anomaly and significantly outperform the market. For more on the short-term reversal anomaly, the strategy to benefit directly from it – and whether traders can still use this…
Today’s article highlights two cheap healthcare stocks that, while having suffered so far this year, have growth drivers at hand that should set them up for rebounds going forward: “The first of these great deals, a pharmaceutical company, has a blockbuster on the market, a newer drug with growing sales, and possible drug approvals in the coming months. And the…